Mersana Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $3,056 | $2,754 | $16,361 | $12,598 |
Gross Profit | 2,769 | 2,754 | 16,361 | 12,598 |
EBITDA | -23,335 | -23,032 | -12,814 | -9,695 |
EBIT | -23,622 | -23,348 | -13,214 | -10,097 |
Net Income | -24,296 | -24,123 | -14,117 | -11,501 |
Net Change In Cash | 3,056 | 2,754 | 16,361 | 12,598 |
Free Cash Flow | -22,602 | -29,326 | -19,251 | -8,577 |
Cash | 76,972 | 102,287 | 107,750 | 78,868 |
Basic Shares | 4,986 | 4,978 | 4,942 | 4,908 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $40,497 | $36,855 | $26,581 | $43 |
Gross Profit | 38,869 | -111,414 | 25,654 | -131,970 |
EBITDA | -63,272 | -166,080 | -199,957 | -167,938 |
EBIT | -64,900 | -167,597 | -200,884 | -168,793 |
Net Income | -69,192 | -171,670 | -207,540 | -169,205 |
Net Change In Cash | 40,497 | 36,855 | 26,581 | 43 |
Cost of Revenue | -76,990 | |||
Free Cash Flow | -82,472 | -171,050 | -51,560 | -140,636 |
Cash | 107,750 | 174,561 | 128,885 | 177,947 |
Basic Shares | 4,901 | 4,644 | 3,746 | 2,823 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$4.87 |
2025-03-31 | -$0.19 |
2024-12-31 | -$0.11 |
